AI assistant
ORPEA — Major Shareholding Notification 2023
Feb 9, 2023
1578_iss_2023-02-09_793a58cd-994a-461b-a999-960193b70aae.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Press release
Puteaux, France, 9 February 2023 (8:00 a.m. CET)
DOWNWARDS THRESHOLDS CROSSING BY CPPIB
ORPEA S.A. (the "Company") has been notified that the Canadian Pension Plan Investment Board ("CPPIB") has crossed downwards the legal thresholds of (i) 20% and 15% of the voting rights, (ii) 10% of the share capital and voting rights and (iii) 5% of the share capital of the Company, following the sale on the market by CPPIB of 7,424,188 ORPEA shares, between 2 February and 7 February 2023.
Following this sale, CPPIB (which held 14.50% of the share capital and 24.16% of the voting rights of the Company) holds 1,950,000 ORPEA shares, representing 3.01% of the share capital and 5.02% of the voting rights of the Company.
About ORPEA
ORPEA is a leading global player, expert in the care of all types of frailty. The Group operates in 22 countries and covers three core businesses: care for the elderly (nursing homes, assisted living, home care), post-acute and rehabilitation care and mental health care (specialized clinics). It has more than 72,000 employees and welcomes more than 255,000 patients and residents each year.
https://www.orpea-group.com/en/
ORPEA is listed on Euronext Paris (ISIN: FR0000184798) and is a member of the SBF 120, STOXX 600 Europe, MSCI Small Cap Europe and CAC Mid 60 indices.
| Investor Relations | Investor Relations | Media Relations |
|---|---|---|
| ORPEA | NewCap | ORPEA |
| Jean-Baptiste Roussille | Dusan Oresansky | Isabelle Herrier-Naufle |
| Head of Investor Relations | Tel.: +33 (0)1 44 71 94 94 | Media Relations Director |
| [email protected] | [email protected] | Tel.: +33 (0)7 70 29 53 74 |
| [email protected] | ||
| Benoit Lesieur | Image 7 | |
| Investor Relations Director | Charlotte Le Barbier |
[email protected] Tel.: +33 (0)6 78 37 27 60
Toll free tel. nb. for shareholders: +33 (0) 805 480 480